Pharmacopeia Protocols & Dosage Guidelines
Clinical dosing & administration matrix
Standard reference metrics for Calcium Gluconate 10% solution yielding 93 mg elemental Ca²⁺ (4.65 mEq) per 10 mL ampule. Adhere strictly to infusion limits and ECG monitoring requirements.
Absolute administration boundaries
NEVER administer IM or Subcutaneous: Intramuscular or subcutaneous injections cause severe tissue sloughing, calcinosis cutis, and local necrosis. Use only verified intravascular or oral routes. Always aspirate before IV injection to verify venous placement.
Filter clinical indication:
Adult Oral Regimen
Route: PO (Oral)
Calculated Dosage:1–2 g elemental calcium daily
Administration Timeframe:Divided into 3–4 equal doses
Infusion Rate Limit:Not applicable (Enteral)
Telemetry Standard:Routine baseline serum Ca²⁺ & albumin
Administration Directives
- Administer with a full glass of water to maximize gastrointestinal absorption.
- Separate from oral iron, tetracyclines, or bisphosphonates by at least 2 hours.
- Monitor for constipation, nausea, or abdominal distention.
Indication Target:Chronic hypocalcemia, maintenance therapy, osteomalacia
Acute Hypocalcemia IV
Route: Slow IV Infusion
Calculated Dosage:1–2 g (10–20 mL of 10% solution)
Administration Timeframe:Administer over 10–20 minutes
Infusion Rate Limit:Maximum <= 200 mg/min (2 mL/min of 10%)
Telemetry Standard:Continuous ECG during active infusion; watch for bradycardia
Administration Directives
- Use a large-bore peripheral vein or central line; confirm active blood return.
- Dilute in 50–100 mL of 5% Dextrose in Water (D5W) or Normal Saline (0.9% NaCl).
- Halt infusion immediately if patient reports burning, severe warmth, or peripheral pain.
Indication Target:Symptomatic hypocalcemia, tetany, post-thyroidectomy spasms
Emergency Hyperkalemia IV
Route: Slow IV Bolus
Calculated Dosage:1 g (10 mL of 10% solution)
Administration Timeframe:Administer over 2–5 minutes
Infusion Rate Limit:Titrate slowly; repeat in 5–10 min if ECG fails to normalize
Telemetry Standard:Continuous rhythm monitoring; does not lower serum potassium
Administration Directives
- Provides rapid myocardial membrane stabilization within 1–3 minutes.
- Duration of cardioprotection is 30–60 minutes; pair promptly with potassium-shifting agents.
- Contraindicated in suspected or confirmed digoxin toxicity due to fatal dysrhythmia risk.
Indication Target:Severe hyperkalemia with ECG changes (peaked T-waves, widened QRS)
Pediatric IV Dosing
Route: Slow IV Infusion
Calculated Dosage:0.1–0.2 mL/kg of 10% solution (10–20 mg/kg)
Administration Timeframe:Infuse slowly over 10–30 minutes
Infusion Rate Limit:Strict ceiling: <= 100 mg/min (1 mL/min of 10%)
Telemetry Standard:Continuous pediatric cardiac monitoring and frequent site inspection
Administration Directives
- Calculate dose strictly against verified patient weight; double-check with a second nurse.
- Absolute contraindication: Never co-infuse or mix with ceftriaxone in neonates <= 28 days.
- Ensure line patency prior to push; avoid umbilical artery catheter infusions.
Indication Target:Pediatric hypocalcemic tetany, cardiac resuscitation adjunct
Telemetry & Infusion Rate Ceiling Table
Side-by-side technical parameters across clinical settings
| Regimen / Setting | Route | Reference Dose | Duration / Rate Ceiling | Monitoring Requirement |
|---|---|---|---|---|
| Adult Oral Regimen | PO (Oral) | 1–2 g elemental calcium daily | Not applicable (Enteral) | Routine baseline serum Ca²⁺ & albumin |
| Acute Hypocalcemia IV | Slow IV Infusion | 1–2 g (10–20 mL of 10% solution) | Maximum <= 200 mg/min (2 mL/min of 10%) | Continuous ECG during active infusion; watch for bradycardia |
| Emergency Hyperkalemia IV | Slow IV Bolus | 1 g (10 mL of 10% solution) | Titrate slowly; repeat in 5–10 min if ECG fails to normalize | Continuous rhythm monitoring; does not lower serum potassium |
| Pediatric IV Dosing | Slow IV Infusion | 0.1–0.2 mL/kg of 10% solution (10–20 mg/kg) | Strict ceiling: <= 100 mg/min (1 mL/min of 10%) | Continuous pediatric cardiac monitoring and frequent site inspection |
Clinical Pearls, Dilution Vehicles & Y-Site Incompatibilities
Essential pharmacy compounding guidelines and physical compatibility standards
Safety specificationsProtocol Ref: CG-IV-SEC-4
Critical infusion precautions
Verify vascular integrity, enforce strict flow velocity limits, and maintain active rhythm monitoring before initiating intravenous Calcium Gluconate administration.
Vascular AccessCentral / Large Bore IV
Large vein vascular access
Administer strictly via a large peripheral vein or central line. Avoid small hand or wrist veins to minimize chemical phlebitis and reduce extravasation risk.
Recommended Gauge18G – 20G or CVC
- Confirm blood return and line patency before starting the infusion
- Inspect insertion site every 10 to 15 minutes during delivery
- Flush lines thoroughly before and after administration with 0.9% NaCl
Rate ControlMax ≤ 200 mg/min
Controlled infusion velocity
Administer slow intravenous push or diluted piggyback infusion. Rapid IV injection precipitates acute vasodilatation, sudden hypotension, and severe cardiac arrest.
Acute Bolus Velocity1.5 – 2.0 mL/min (10%)
- Emergency hypocalcemia: 1–2 g over 10–20 minutes slow IV
- Severe hyperkalemia: 1 g IV over 2–5 minutes with active telemetry
- Compatible diluents: 5% Dextrose in water (D5W) or 0.9% Sodium Chloride
MonitoringContinuous Rhythm
Continuous ECG & telemetry
Maintain continuous cardiac monitoring during IV boluses. Calcium shifts rapidly alter cardiac conduction, triggering bradycardia, QT shortening, and ventricular dysrhythmias.
Telemetry TriggerStop if HR < 60 bpm
- Monitor for abrupt sinus bradycardia, PR prolongation, and heart block
- Exercise heightened vigilance in patients receiving cardiac glycosides
- Check ionized serum calcium within 4 to 6 hours after acute correction
Black Box WarningNEVER IM / SubQ
Strict route prohibition
Do not administer intramuscularly or subcutaneously under any circumstances. Calcium precipitation produces severe tissue necrosis, sloughing, and calcinosis cutis.
Route StatusIV Only (Zero IM/SC)
- Intramuscular injection results in muscle fibrosis, abscess, and necrosis
- Subcutaneous infiltration causes irreversible ulceration and tissue loss
- Neonates ≤ 28 days: Do not co-administer with ceftriaxone (lethal precipitates)
Extravasation emergency protocol
Immediate action requiredIf swelling, erythema, burning, or resistance occurs at the IV site, stop the infusion immediately. Disconnect tubing, aspirate residual drug from the cannula, elevate the extremity, and notify the medical team. Do not flush the line.
1Halt infusion immediately
2Aspirate cannula & elevate
3Initiate localized therapy